MANKIND - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.5
| Stock Code | MANKIND | Market Cap | 89,131 Cr. | Current Price | 2,163 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 53.5 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,193 ₹ | DMA 200 | 2,340 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 459 Cr. | PAT Prev Qtr | 413 Cr. |
| RSI | 51.0 | MACD | -25.8 | Volume | 7,92,794 | Avg Vol 1Wk | 4,41,417 |
| Low price | 2,047 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.36 | Debt to equity | 0.47 |
| 52w Index | 17.0 % | Qtr Profit Var | -25.2 % | EPS | 40.4 ₹ | Industry PE | 29.2 |
📊 Mankind Pharma (MANKIND) shows a cautious outlook for swing trading. The stock trades at ₹2,163, slightly below its 50 DMA (₹2,193) and 200 DMA (₹2,340), reflecting short-term weakness. RSI at 51.0 indicates neutral momentum, while MACD at -25.8 signals bearish pressure. Valuation is stretched with a P/E of 53.5 compared to industry average of 29.2, and PEG ratio of 6.36 suggests expensive growth. Fundamentals remain moderate with ROE at 13.9% and ROCE at 15.0%. EPS of ₹40.4 and sequential PAT growth provide positives, though FII selling (-1.49%) and profit variation (-25.2%) weigh on sentiment.
✅ Optimal Entry Price: Around ₹2,100–2,140 (near support zone, slightly below current price).
🚪 Exit Strategy (if already holding): Consider exit near ₹2,250–2,300 (resistance zone close to 50 DMA). If price falls below ₹2,080, apply stop-loss to protect capital.
Positive
- 📈 Sequential PAT growth (₹459 Cr. vs ₹413 Cr.).
- 💹 ROE (13.9%) and ROCE (15.0%) show operational efficiency.
- 📊 EPS of ₹40.4 supports valuation strength.
- 🏦 DII holdings increased (+1.35%).
Limitation
- ⚠️ Trading below both 50 DMA and 200 DMA.
- 📉 High P/E (53.5 vs industry 29.2).
- 📉 PEG ratio (6.36) indicates expensive growth.
- 📉 Dividend yield is very low (0.05%).
Company Negative News
- 📉 FII holdings decreased (-1.49%).
- ⚠️ Quarterly profit variation declined (-25.2%).
Company Positive News
- 📈 PAT improved sequentially, showing operational growth.
- 🏦 DII accumulation signals domestic investor confidence.
Industry
- 🏭 Pharma sector average PE is 29.2, Mankind trades at a premium (53.5).
- 📊 Sector demand remains resilient, but valuations are stretched.
Conclusion
⚖️ Mankind Pharma is a moderately suitable candidate for swing trading. Entry near ₹2,100–2,140 offers favorable risk-reward, while exits should be targeted near ₹2,250–2,300. Strong EPS and sequential PAT growth provide positives, but high valuation, weak technicals, and FII selling limit short-term upside. Traders should remain cautious and apply strict stop-loss discipline below ₹2,080.